Compare Amylx Pharmaceuticals Inc (AMLX) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Synopsys, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.34 (market cap $1.98B), while Synopsys, Inc. trades at $441.09 (market cap $85.30B). The key difference: Synopsys, Inc. is far larger — about 43.1× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| AMLX | SNPS | |
|---|---|---|
Market Cap | $1.98B | $85.30B |
Sector | Health | Technology |
52-Week High | $18.70 | $645.59 |
52-Week Low | $7.64 | $380.47 |
Enterprise Value | $1.70B | $93.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Synopsys (SNPS) trades at $445.40, up 0.5% on the day, amid a bearish technical signal with support at $432 and resistance at $449. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $3.35 versus $3.15 expected, and robust revenue growth to $7.05B in 2025. However, net income margin declined to 8.91% from 36.93% in 2024, and cash flow turned negative at -$1.01B due to heavy investing activity.
Outlook remains positive with analyst consensus price target of $558.33 implying 25% upside, supported by the company's strategic pivot to AI-driven design tools. Key risks include execution of the AI transition, high valuation multiples like a P/E of 101.95, and semiconductor cycle volatility. The stock offers growth exposure but requires monitoring of margin trends and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
